Vivos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Vivos Therapeutics

16/08/2023 22:26

* Vivos Therapeutics Inc  VVOS.OQ  reported a quarterly
adjusted
loss of 18 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 14 cents per share.
    * Revenue fell 18.9% to $3.40 million from a year ago;
analysts
expected $4.15 million. 
    * Vivos Therapeutics Inc's reported EPS for the quarter was
a loss
of 18 cents​.
    * The mean earnings estimate of analysts had risen by
about 14.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Vivos Therapeutics Inc shares had fallen by 36.0% this
quarter and lost 18.8% so far this year.
    * The company reported a quarterly loss of $5.53 million.
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $1.95 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 16 at 09:26 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.14          -0.18          Missed
 Mar. 31 2023      -0.18          -0.07          Beat
 Dec. 31 2022      -0.22          -0.20          Beat